Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 300


Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial.

Verma S, Bain SC, Buse JB, Idorn T, Rasmussen S, Ørsted DD, Nauck MA.

JAMA Cardiol. 2019 Nov 13. doi: 10.1001/jamacardio.2019.3080. [Epub ahead of print]


Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11).

Amod A, Buse JB, McGuire DK, Pieber TR, Pop-Busui R, Pratley RE, Zinman B, Hansen MB, Jia T, Mark T, Poulter NR; DEVOTE Study Group.

Diabetes Ther. 2019 Oct 30. doi: 10.1007/s13300-019-00715-x. [Epub ahead of print]


Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes.

Heller SR, Buse JB, Ratner R, Seaquist E, Bardtrum L, Hansen CT, Tutkunkardas D, Moses AC.

Diabetes Care. 2019 Oct 28. pii: dc182361. doi: 10.2337/dc18-2361. [Epub ahead of print]


Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.

Clegg LE, Penland RC, Bachina S, Boulton DW, Thuresson M, Heerspink HJL, Gustavson S, Sjöström CD, Ruggles JA, Hernandez AF, Buse JB, Mentz RJ, Holman RR.

Cardiovasc Diabetol. 2019 Oct 22;18(1):138. doi: 10.1186/s12933-019-0942-x.


Reasons for Increases in Complications of Diabetes.

Buse JB.

JAMA. 2019 Oct 15;322(15):1518-1519. doi: 10.1001/jama.2019.13036. No abstract available.


Insights Into Patients' Experience With Type 1 Diabetes: Exit Interviews From Phase III Studies of Sotagliflozin.

Ervin C, Joish VN, Evans E, DiBenedetti D, Reaney M, Preblick R, Castro R, Danne T, Buse JB, Lapuerta P.

Clin Ther. 2019 Oct 3. pii: S0149-2918(19)30479-5. doi: 10.1016/j.clinthera.2019.09.003. [Epub ahead of print]


Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial.

Zinman B, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, Pedersen KB, Tarp-Johansen MJ, Araki E; PIONEER 8 Investigators.

Diabetes Care. 2019 Dec;42(12):2262-2271. doi: 10.2337/dc19-0898. Epub 2019 Sep 17.


A Mixed-Methods, Randomized Clinical Trial to Examine Feasibility of a Mindfulness-Based Stress Management and Diabetes Risk Reduction Intervention for African Americans with Prediabetes.

Woods-Giscombe CL, Gaylord SA, Li Y, Brintz CE, Bangdiwala SI, Buse JB, Mann JD, Lynch C, Phillips P, Smith S, Leniek K, Young L, Al-Barwani S, Yoo J, Faurot K.

Evid Based Complement Alternat Med. 2019 Aug 14;2019:3962623. doi: 10.1155/2019/3962623. eCollection 2019.


Characteristics and Delivery of Diabetes Shared Medical Appointments in North Carolina.

Drake C, Kirk JK, Buse JB, Edelman D, Shea CM, Spratt S, Young LA, Kahkoska AR.

N C Med J. 2019 Sep-Oct;80(5):261-268. doi: 10.18043/ncm.80.5.261.


Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults.

Wang T, Yang JY, Buse JB, Pate V, Tang H, Barnes EL, Sandler RS, Stürmer T.

Diabetes Care. 2019 Nov;42(11):2065-2074. doi: 10.2337/dc19-0162. Epub 2019 Aug 30.


Glucose-Responsive Insulin and Delivery Systems: Innovation and Translation.

Wang J, Wang Z, Yu J, Kahkoska AR, Buse JB, Gu Z.

Adv Mater. 2019 Aug 18:e1902004. doi: 10.1002/adma.201902004. [Epub ahead of print] Review.


Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial.

Nauck MA, Muus Ghorbani ML, Kreiner E, Saevereid HA, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators.

Diabetes Care. 2019 Oct;42(10):1912-1920. doi: 10.2337/dc19-0415. Epub 2019 Aug 9.


Bringing closure: towards achieving a better understanding of Israel.

Rosenstock J, Zimmet P, Skyler JS, Atkinson M, Schatz D, Buse JB, Kahn S, Hirsch IB, Leroith D, Alberti KG.

Lancet. 2019 Aug 17;394(10198):559. doi: 10.1016/S0140-6736(19)31760-X. Epub 2019 Jul 31. No abstract available.


Charge-switchable polymeric complex for glucose-responsive insulin delivery in mice and pigs.

Wang J, Yu J, Zhang Y, Zhang X, Kahkoska AR, Chen G, Wang Z, Sun W, Cai L, Chen Z, Qian C, Shen Q, Khademhosseini A, Buse JB, Gu Z.

Sci Adv. 2019 Jul 10;5(7):eaaw4357. doi: 10.1126/sciadv.aaw4357. eCollection 2019 Jul.


Longitudinal Phenotypes of Type 1 Diabetes in Youth Based on Weight and Glycemia and Their Association With Complications.

Kahkoska AR, Nguyen CT, Adair LA, Aiello AE, Burger KS, Buse JB, Dabelea D, Dolan LM, Malik FS, Mottl AK, Pihoker C, Reboussin BA, Sauder KA, Kosorok MR, Mayer-Davis EJ.

J Clin Endocrinol Metab. 2019 Dec 1;104(12):6003-6016. doi: 10.1210/jc.2019-00734.


Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial.

Tack CJ, Jacob S, Desouza C, Bain SC, Buse JB, Nauck MA, Petrie JR, Poulter NR, Pratley RE, Stegmann HVBK, Bosch-Traberg H, Startseva E, Zinman B; LEADER Publication Committee on behalf of the LEADER Trial Investigators.

Diabetes Obes Metab. 2019 Nov;21(11):2450-2458. doi: 10.1111/dom.13826. Epub 2019 Jul 7.


Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16).

Pollock RF, Valentine WJ, Marso SP, Andersen A, Gundgaard J, Hallén N, Tutkunkardas D, Magnuson EA, Buse JB; DEVOTE study group.

Appl Health Econ Health Policy. 2019 Oct;17(5):615-627. doi: 10.1007/s40258-019-00494-3.


Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin.

Alexopoulos AS, Buse JB.

Metabolism. 2019 Sep;98:104-111. doi: 10.1016/j.metabol.2019.06.012. Epub 2019 Jun 27. Review.


Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.

Pieber TR, Bode B, Mertens A, Cho YM, Christiansen E, Hertz CL, Wallenstein SOR, Buse JB; PIONEER 7 investigators.

Lancet Diabetes Endocrinol. 2019 Jul;7(7):528-539. doi: 10.1016/S2213-8587(19)30194-9. Epub 2019 Jun 9. Erratum in: Lancet Diabetes Endocrinol. 2019 Sep;7(9):e21.


Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example.

Aroda VR, Saugstrup T, Buse JB, Donsmark M, Zacho J, Davies MJ.

Diabetes Obes Metab. 2019 Oct;21(10):2203-2210. doi: 10.1111/dom.13804. Epub 2019 Jun 30. Review.


A Genetic Locus on Chromosome 2q24 Predicting Peripheral Neuropathy Risk in Type 2 Diabetes: Results From the ACCORD and BARI 2D Studies.

Tang Y, Lenzini PA, Pop-Busui R, Ray PR, Campbell H, Perkins BA, Callaghan B, Wagner MJ, Motsinger-Reif AA, Buse JB, Price TJ, Mychaleckyj JC, Cresci S, Shah H, Doria A.

Diabetes. 2019 Aug;68(8):1649-1662. doi: 10.2337/db19-0109. Epub 2019 May 24.


Assessing the Association Between Dipeptidyl Peptidase 4 Inhibitor Use and Inflammatory Bowel Disease Through Drug Adverse Event Reporting.

Wang T, Lu W, Li D, Tang H, Yang JY, Buse JB, Stürmer T.

Diabetes Care. 2019 Jun;42(6):e89-e91. doi: 10.2337/dc18-1609. No abstract available.


Glucose transporter inhibitor-conjugated insulin mitigates hypoglycemia.

Wang J, Yu J, Zhang Y, Kahkoska AR, Wang Z, Fang J, Whitelegge JP, Li S, Buse JB, Gu Z.

Proc Natl Acad Sci U S A. 2019 May 28;116(22):10744-10748. doi: 10.1073/pnas.1901967116. Epub 2019 May 16.


Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes.

Garry EM, Buse JB, Gokhale M, Lund JL, Nielsen ME, Pate V, Stürmer T.

Diabetes Obes Metab. 2019 Sep;21(9):2096-2106. doi: 10.1111/dom.13774. Epub 2019 Jun 17.


Evidence supports prediabetes treatment.

Neumiller JJ, Kalyani RR, Herman WH, Grant RW, Wysham CH, Inzucchi SE, Hirsch IB, Fonseca VA, Buse JB, Barrett EJ.

Science. 2019 Apr 26;364(6438):341-342. doi: 10.1126/science.aax3548. No abstract available.


Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL).

Bethel MA, Patel RA, Thompson VP, Merrill P, Reed SD, Li Y, Ahmadi S, Katona BG, Gustavson SM, Ohman P, Iqbal N, Gagel RF, Hernandez AF, Buse JB, Holman RR; EXSCEL Study Group.

Diabetes Care. 2019 Jun;42(6):1075-1080. doi: 10.2337/dc18-2028. Epub 2019 Apr 22.


Identification of clinically relevant dysglycemia phenotypes based on continuous glucose monitoring data from youth with type 1 diabetes and elevated hemoglobin A1c.

Kahkoska AR, Adair LA, Aiello AE, Burger KS, Buse JB, Crandell J, Maahs DM, Nguyen CT, Kosorok MR, Mayer-Davis EJ.

Pediatr Diabetes. 2019 Aug;20(5):556-566. doi: 10.1111/pedi.12856. Epub 2019 Apr 29.


Correction to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB.

Diabetologia. 2019 May;62(5):873. doi: 10.1007/s00125-019-4845-x.


Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials.

Verma S, Bain SC, Monk Fries T, Mazer CD, Nauck MA, Pratley RE, Rasmussen S, Saevereid HA, Zinman B, Buse JB.

Diabetes Obes Metab. 2019 Jul;21(7):1745-1751. doi: 10.1111/dom.13698. Epub 2019 Apr 2.


Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7).

Pratley RE, Emerson SS, Franek E, Gilbert MP, Marso SP, McGuire DK, Pieber TR, Zinman B, Hansen CT, Hansen MV, Mark T, Moses AC, Buse JB; DEVOTE Study Group.

Diabetes Obes Metab. 2019 Jul;21(7):1625-1633. doi: 10.1111/dom.13699. Epub 2019 Apr 15.


Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.

Danne T, Cariou B, Buse JB, Garg SK, Rosenstock J, Banks P, Kushner JA, McGuire DK, Peters AL, Sawhney S, Strumph P.

Diabetes Care. 2019 May;42(5):919-930. doi: 10.2337/dc18-2149. Epub 2019 Mar 4.


Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10).

Brown-Frandsen K, Emerson SS, McGuire DK, Pieber TR, Poulter NR, Pratley RE, Zinman B, Ranthe MF, Grøn R, Lange M, Moses AC, Örsy P, Buse JB; DEVOTE Study Group.

Diabetes Obes Metab. 2019 Jun;21(6):1437-1444. doi: 10.1111/dom.13677. Epub 2019 Apr 1.


Identifying individual risk rare variants using protein structure guided local tests (POINT).

Marceau West R, Lu W, Rotroff DM, Kuenemann MA, Chang SM, Wu MC, Wagner MJ, Buse JB, Motsinger-Reif AA, Fourches D, Tzeng JY.

PLoS Comput Biol. 2019 Feb 19;15(2):e1006722. doi: 10.1371/journal.pcbi.1006722. eCollection 2019 Feb.


International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors.

Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH, Alexander CM, Battelino T, Ampudia-Blasco FJ, Bode BW, Cariou B, Close KL, Dandona P, Dutta S, Ferrannini E, Fourlanos S, Grunberger G, Heller SR, Henry RR, Kurian MJ, Kushner JA, Oron T, Parkin CG, Pieber TR, Rodbard HW, Schatz D, Skyler JS, Tamborlane WV, Yokote K, Phillip M.

Diabetes Care. 2019 Jun;42(6):1147-1154. doi: 10.2337/dc18-2316. Epub 2019 Feb 6. Review.


Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: Evolving questions, evolving answers.

Yang JY, Wang T, Pate V, Gower EW, Crowley MJ, Buse JB, Stürmer T.

Diabetes Obes Metab. 2019 May;21(5):1223-1236. doi: 10.1111/dom.13647. Epub 2019 Mar 4.


Performance of a computable phenotype for identification of patients with diabetes within PCORnet: The Patient-Centered Clinical Research Network.

Wiese AD, Roumie CL, Buse JB, Guzman H, Bradford R, Zalimeni E, Knoepp P, Morris HL, Donahoo WT, Fanous N, Epstein BF, Katalenich BL, Ayala SG, Cook MM, Worley KJ, Bachmann KN, Grijalva CG, Rothman RL, Chakkalakal RJ.

Pharmacoepidemiol Drug Saf. 2019 May;28(5):632-639. doi: 10.1002/pds.4718. Epub 2019 Jan 24.


Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator.

Vella A, Freeman JLR, Dunn I, Keller K, Buse JB, Valcarce C.

Sci Transl Med. 2019 Jan 16;11(475). pii: eaau3441. doi: 10.1126/scitranslmed.aau3441.


Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke.

Verma S, Poulter NR, Bhatt DL, Bain SC, Buse JB, Leiter LA, Nauck MA, Pratley RE, Zinman B, Ørsted DD, Monk Fries T, Rasmussen S, Marso SP.

Circulation. 2018 Dec 18;138(25):2884-2894. doi: 10.1161/CIRCULATIONAHA.118.034516.


Assessing the Association Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Through the FDA Adverse Event Reporting System.

Wang T, Lu W, Tang H, Buse JB, Stürmer T, Gower EW.

Diabetes Care. 2019 Feb;42(2):e21-e23. doi: 10.2337/dc18-1893. Epub 2018 Dec 7. No abstract available.


Advances in transdermal insulin delivery.

Zhang Y, Yu J, Kahkoska AR, Wang J, Buse JB, Gu Z.

Adv Drug Deliv Rev. 2019 Jan 15;139:51-70. doi: 10.1016/j.addr.2018.12.006. Epub 2018 Dec 8. Review.


Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial.

Gilbert MP, Bain SC, Franek E, Jodar-Gimeno E, Nauck MA, Pratley R, Réa RR, Kerr Saraiva JF, Rasmussen S, Tornøe K, von Scholten BJ, Buse JB; and the LEADER Publication Committee on behalf of the LEADER Trial Investigators.

Ann Intern Med. 2019 Mar 19;170(6):423-426. doi: 10.7326/M18-1569. Epub 2018 Dec 4. No abstract available.


Health Literacy, Glycemic Control, and Physician-Advised Glucose Self-Monitoring Use in Type 2 Diabetes.

Alvarez PM, Young LA, Mitchell M, Blakeney TG, Buse JB, Vu MB, Weaver MA, Rees J, Grimm K, Donahue KE.

Diabetes Spectr. 2018 Nov;31(4):344-347. doi: 10.2337/ds18-0064.


Impact of metformin use on the cardiovascular effects of dipeptidyl peptidase-4 inhibitors: An analysis of Medicare claims data from 2007 to 2015.

Crowley MJ, Gokhale M, Pate V, Stürmer T, Buse JB.

Diabetes Obes Metab. 2018 Nov 20. doi: 10.1111/dom.13589. [Epub ahead of print]


Liraglutide and Glycaemic Outcomes in the LEADER Trial.

Zinman B, Nauck MA, Bosch-Traberg H, Frimer-Larsen H, Ørsted DD, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators.

Diabetes Ther. 2018 Dec;9(6):2383-2392. doi: 10.1007/s13300-018-0524-z. Epub 2018 Nov 3.


Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial.

Mentz RJ, Bethel MA, Merrill P, Lokhnygina Y, Buse JB, Chan JC, Felício JS, Goodman SG, Choi J, Gustavson SM, Iqbal N, Lopes RD, Maggioni AP, Öhman P, Pagidipati NJ, Poulter NR, Ramachandran A, Reicher B, Holman RR, Hernandez AF; EXSCEL Study Group.

J Am Heart Assoc. 2018 Oct 2;7(19):e009304. doi: 10.1161/JAHA.118.009304.


Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes.

Mottl AK, Buse JB, Ismail-Beigi F, Sigal RJ, Pedley CF, Papademetriou V, Simmons DL, Katz L, Mychaleckyj JC, Craven TE.

Clin J Am Soc Nephrol. 2018 Nov 7;13(11):1693-1702. doi: 10.2215/CJN.06200518. Epub 2018 Oct 25.


Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB.

Diabetes Care. 2018 Dec;41(12):2669-2701. doi: 10.2337/dci18-0033. Epub 2018 Oct 4.


Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB.

Diabetologia. 2018 Dec;61(12):2461-2498. doi: 10.1007/s00125-018-4729-5. Erratum in: Diabetologia. 2019 May;62(5):873.


Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.

Morieri ML, Gao H, Pigeyre M, Shah HS, Sjaarda J, Mendonca C, Hastings T, Buranasupkajorn P, Motsinger-Reif AA, Rotroff DM, Sigal RJ, Marcovina SM, Kraft P, Buse JB, Wagner MJ, Gerstein HC, Mychaleckyj JC, Parè G, Doria A.

Diabetes Care. 2018 Nov;41(11):2404-2413. doi: 10.2337/dc18-0709. Epub 2018 Sep 27.


Health-related quality of life in people with type 2 diabetes participating in the LEADER trial.

Nauck MA, Buse JB, Mann JFE, Pocock S, Bosch-Traberg H, Frimer-Larsen H, Ye Q, Gray A; LEADER Publication Committee for the LEADER Trial Investigators.

Diabetes Obes Metab. 2019 Mar;21(3):525-532. doi: 10.1111/dom.13547. Epub 2018 Oct 25.

Supplemental Content

Support Center